Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cencora inc. - COR

COR

Close Chg Chg %
289.34 -10.75 -3.72%

Closed Market

278.59

-10.75 (3.72%)

Volume: 4.40M

Last Updated:

Apr 4, 2025, 3:59 PM EDT

Trade Now

Company Overview: cencora inc. - COR

COR Key Data

Open

$290.72

 Day Range

276.01 - 296.65

52 Week Range

214.77 - 296.65

 Market Cap

$56.11B

Shares Outstanding

193.92M

 Public Float

182.79M

Beta

0.54

 Rev. Per Employee

N/A

P/E Ratio

41.17

 EPS

$7.09

Yield

73.27%

 Dividend

$0.55

EX-DIVIDEND DATE

Feb 14, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.93M

  

COR Performance

1 Week
 
 1.16%
 
1 Month
 
 9.35%
 
3 Months
 
 17.87%
 
1 Year
 
 14.46%
 
5 Years
 
 217.04%
 

COR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About cencora inc. - COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

COR At a Glance

Cencora, Inc.
1 West First Avenue
Conshohocken, Pennsylvania 19428-1800
Phone 1-610-727-7000 Revenue 293.96B
Industry Medical Distributors Net Income 1.51B
Sector Distribution Services 2024 Sales Growth 12.124%
Fiscal Year-end 09 / 2025 Employees 46,000
View SEC Filings

COR Valuation

P/E Current 41.169
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 29.872
Price to Sales Ratio 0.153
Price to Book Ratio 67.929
Price to Cash Flow Ratio 12.937
Enterprise Value to EBITDA 11.468
Enterprise Value to Sales 0.162
Total Debt to Enterprise Value 0.118

COR Efficiency

Revenue/Employee 6,390,404.326
Income Per Employee 32,806.957
Receivables Turnover 12.269
Total Asset Turnover 4.534

COR Liquidity

Current Ratio 0.879
Quick Ratio 0.529
Cash Ratio 0.06

COR Profitability

Gross Margin 2.96
Operating Margin 1.034
Pretax Margin 0.682
Net Margin 0.513
Return on Assets 2.328
Return on Equity 258.424
Return on Total Capital 24.074
Return on Invested Capital 27.24

COR Capital Structure

Total Debt to Total Equity 870.489
Total Debt to Total Capital 89.696
Total Debt to Total Assets 8.38
Long-Term Debt to Equity 749.565
Long-Term Debt to Total Capital 77.236
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cencora Inc. - COR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
213.99B 238.59B 262.17B 293.96B
Sales Growth
+12.69% +11.50% +9.89% +12.12%
Cost of Goods Sold (COGS) incl D&A
207.72B 230.99B 254.42B 285.26B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
505.17M 697.94M 972.39M 1.11B
Depreciation
326.82M 390.64M 418.83M 448.20M
Amortization of Intangibles
178.35M 307.30M 553.56M 663.47M
COGS Growth
+12.22% +11.20% +10.14% +12.12%
Gross Income
6.27B 7.60B 7.76B 8.70B
Gross Income Growth
+30.83% +21.24% +2.05% +12.18%
Gross Profit Margin
+2.93% +3.19% +2.96% +2.96%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.59B 4.85B 5.31B 5.66B
Research & Development
- - - -
-
Other SG&A
3.59B 4.85B 5.31B 5.66B
SGA Growth
+29.89% +34.91% +9.51% +6.61%
Other Operating Expense
- - - -
-
Unusual Expense
270.09M 380.46M 105.54M 827.00M
EBIT after Unusual Expense
2.40B 2.37B 2.34B 2.21B
Non Operating Income/Expense
(515.00K) 43.83M 95.51M 39.52M
Non-Operating Interest Income
8.47M 21.31M 46.72M 91.69M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
182.54M 231.98M 275.65M 248.68M
Interest Expense Growth
+15.15% +27.08% +18.82% -9.78%
Gross Interest Expense
182.54M 231.98M 275.65M 248.68M
Interest Capitalized
- - - -
-
Pretax Income
2.22B 2.18B 2.16B 2.00B
Pretax Income Growth
+141.97% -1.75% -1.02% -7.26%
Pretax Margin
+1.04% +0.91% +0.82% +0.68%
Income Tax
677.25M 516.52M 428.26M 484.70M
Income Tax - Current - Domestic
215.03M 166.25M 302.06M 389.42M
Income Tax - Current - Foreign
127.35M 154.08M 245.06M 197.61M
Income Tax - Deferred - Domestic
158.94M 181.46M 3.85M (16.54M)
Income Tax - Deferred - Foreign
175.92M 14.73M (122.71M) (85.78M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.54B 1.67B 1.73B 1.52B
Minority Interest Expense
4.68M (32.28M) (12.72M) 10.15M
Net Income
1.54B 1.70B 1.75B 1.51B
Net Income Growth
+145.18% +10.32% +2.74% -13.53%
Net Margin Growth
+0.72% +0.71% +0.67% +0.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.54B 1.70B 1.75B 1.51B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.54B 1.70B 1.75B 1.51B
EPS (Basic)
7.4783 8.1489 8.6183 7.6025
EPS (Basic) Growth
+144.93% +8.97% +5.76% -11.79%
Basic Shares Outstanding
205.92M 208.47M 202.51M 198.50M
EPS (Diluted)
7.387 8.0433 8.5306 7.5349
EPS (Diluted) Growth
+144.38% +8.88% +6.06% -11.67%
Diluted Shares Outstanding
208.47M 211.21M 204.59M 200.28M
EBITDA
3.18B 3.45B 3.42B 4.15B
EBITDA Growth
+31.08% +8.47% -0.89% +21.44%
EBITDA Margin
+1.49% +1.45% +1.30% +1.41%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 285.571
Number of Ratings 19 Current Quarters Estimate 3.80
FY Report Date 06 / 2025 Current Year's Estimate 15.418
Last Quarter’s Earnings 4.063 Median PE on CY Estimate N/A
Year Ago Earnings 13.76 Next Fiscal Year Estimate 16.91
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 16 14
Mean Estimate 3.80 3.78 15.42 16.91
High Estimates 3.97 4.11 15.56 17.54
Low Estimate 3.34 3.34 15.24 16.71
Coefficient of Variance 4.03 4.20 0.62 1.30

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 1 2 1
HOLD 8 7 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cencora Inc. - COR

Date Name Shares Transaction Value
Mar 21, 2025 Robert P. Mauch President & CEO; Director 49,326 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.93 per share 12,870,633.18
Mar 21, 2025 Robert P. Mauch President & CEO; Director 51,070 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.93 per share 13,325,695.10
Mar 21, 2025 Robert P. Mauch President & CEO; Director 54,296 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $86.09 per share 4,674,342.64
Mar 21, 2025 Robert P. Mauch President & CEO; Director 38,702 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 12, 2025 Lazarus Krikorian SVP & Chief Accounting Officer 20,154 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.06 per share 5,241,249.24
Mar 11, 2025 D. Mark Durcan Director 22,862 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lorence H. Kim Director 3,524 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Franklin K. Clyburn Director 1,157 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Redonda G. Miller Director 3,194 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lauren M. Tyler Director 2,771 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Werner Baumann Director 2,771 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Dennis M. Nally Director 13,130 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lon R. Greenberg Director 20,851 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Steven H. Collis Executive Chairman; Director 163,520 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Steven H. Collis Executive Chairman; Director 319,913 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $251.08 per share 80,323,756.04
Mar 3, 2025 Steven H. Collis Executive Chairman; Director 332,492 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $86.09 per share 28,624,236.28
Mar 3, 2025 Steven H. Collis Executive Chairman; Director 319,913 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $251.08 per share 80,323,756.04
Jul 8, 2024 Leslie E. Donato EVP & Chief Strategy Officer 9,525 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $191.5 per share 1,824,037.50
Jul 8, 2024 Silvana Battaglia Executive Vice President 12,421 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $191.5 per share 2,378,621.50
Jul 8, 2024 Elizabeth S. Campbell Executive Vice President 8,304 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $191.5 per share 1,590,216.00

Cencora Inc. in the News